Compare PESI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | PROK |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.3M | 359.4M |
| IPO Year | 1996 | 2021 |
| Metric | PESI | PROK |
|---|---|---|
| Price | $12.12 | $1.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 319.5K | ★ 1.2M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $642,000.00 | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $81.87 | $7.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $8.58 | $1.30 |
| 52 Week High | $21.32 | $3.48 |
| Indicator | PESI | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 21.61 | 37.72 |
| Support Level | $9.58 | $1.30 |
| Resistance Level | $12.97 | $1.76 |
| Average True Range (ATR) | 0.68 | 0.11 |
| MACD | -0.25 | -0.03 |
| Stochastic Oscillator | 1.51 | 19.78 |
Perma-Fix Environmental Services Inc is a nuclear services company and provider of nuclear and mixed waste management services. The company's nuclear waste services include treatment and management of radioactive and mixed waste (waste containing both hazardous and low-level radioactive waste). The company operates through two segments: i) The treatment segment: It offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and ii) the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.